Top

Published in:

01-03-2019 | Review

Multiple clinical features of Huntington’s disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration

Authors: Sonia Podvin, Holly T. Reardon, Katrina Yin, Charles Mosier, Vivian Hook

Published in: Journal of Neurology | Issue 3/2019

Abstract

Huntington’s disease (HD) is a fatal neurodegenerative disease caused by mutant HTT gene expansions of CAG triplet repeat numbers that are inherited in an autosomal dominant manner. HD patients display multiple clinical features that are correlated with HTT CAG repeat numbers that include age of disease onset, motor dysfunction, cognitive deficits, compromised daily living capacity, and brain neurodegeneration. It is important to understand the significant relationships of the multiple HD clinical deficits correlated with the number of mutant HTT CAG expansions that are the genetic basis for HD disabilities. Therefore, this review highlights the significant correlations of the HD clinical features of age of onset, motor and cognitive disabilities, decline in living capabilities, weight loss, risk of death, and brain neurodegeneration with respect to their associations with CAG repeat lengths of the HTT gene. Quantitative HTT gene expression patterns analyzed in normal adult human brain regions demonstrated its distribution in areas known to undergo neurodegeneration in HD, as well as in other brain regions. Future investigation of the relationships of the spectrum of clinical HD features with mutant HTT molecular mechanisms will be important to gain understanding of how mutant CAG expansions of the HTT gene result in the devastating disabilities of HD patients.

Available only for authorised users

Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369–384CrossRefPubMed

Petersén A, Mani K, Brundin P (1999) Recent advances on the pathogenesis of Huntington’s disease. Exp Neurol 157:1–18. https://doi.org/10.1006/exnr.1998.7006 CrossRefPubMed

Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83–98. https://doi.org/10.1016/S1474-4422(10)70245-3 CrossRefPubMed

Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev 90:905–981. https://doi.org/10.1152/physrev.00041.2009 CrossRefPubMed

Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ (2015) Huntington disease. Nat Rev Dis Primers 1:15005. https://doi.org/10.1038/nrdp.2015.5 CrossRefPubMed

The Huntington’s Disease Collaborative Research Group (1999) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983

Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayán J, Brocklebank D, Cherny SS, Cardon LR, Gray J, Dlouhy SR, Wiktorski S, Hodes ME, Conneally PM, Penney JB, Gusella J, Cha J-H, Irizarry M, Rosas D, Hersch S, Hollingsworth Z, MacDonald M, Young AB, Andresen JM, Housman DE, De Young MM, Bonilla E, Stillings T, Negrette A, Snodgrass SR, Martinez-Jaurrieta MD, Ramos-Arroyo MA, Bickham J, Ramos JS, Marshall F, Shoulson I, Rey GJ, Feigin A, Arnheim N, Acevedo-Cruz A, Acosta L, Alvir J, Fischbeck K, Thompson LM, Young A, Dure L, O’Brien CJ, Paulsen J, Brickman A, Krch D, Peery S, Hogarth P, Higgins DS, Landwehrmeyer B, U.S.-Venezuela Collaborative Research Project (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci USA 101:3498–3503. https://doi.org/10.1073/pnas.0308679101 CrossRefPubMedPubMedCentral

Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 4:398–403. https://doi.org/10.1038/ng0893-398 CrossRefPubMed

Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, Bylsma FW, Pearlson GD, Ross CA (1997) Longitudinal change in basal ganglia volume in patients with Huntington’s disease. Neurology 48:394–399CrossRefPubMed

10.

Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA (1996) Trinucleotide repeat length and clinical progression in Huntington’s disease. Neurology 46:527–531CrossRefPubMed

11.

Illarioshkin SN, Igarashi S, Onodera O, Markova ED, Nikolskaya NN, Tanaka H, Chabrashwili TZ, Insarova NG, Endo K, Ivanova-Smolenskaya IA (1994) Trinucleotide repeat length and rate of progression of Huntington’s disease. Ann Neurol 36:630–635. https://doi.org/10.1002/ana.410360412 CrossRefPubMed

12.

Kieburtz K, MacDonald M, Shih C, Feigin A, Steinberg K, Bordwell K, Zimmerman C, Srinidhi J, Sotack J, Gusella J (1994) Trinucleotide repeat length and progression of illness in Huntington’s disease. J Med Genet 31:872–874CrossRefPubMedPubMedCentral

13.

Lee J-M, Ramos EM, Lee J-H, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJA, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS, PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB, REGISTRY study of the European Huntington’s Disease Network, Myers RH, HD-MAPS Study Group, MacDonald ME, Gusella JF, COHORT study of the HSG (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78:690–695. https://doi.org/10.1212/WNL.0b013e318249f683 CrossRefPubMedPubMedCentral

14.

Pekmezovic T, Svetel M, Maric J, Dujmovic-Basuroski I, Dragasevic N, Keckarevic M, Romac S, Kostic VS (2007) Survival of Huntington’s disease patients in Serbia: longer survival in female patients. Eur J Epidemiol 22:523–526. https://doi.org/10.1007/s10654-007-9157-7 CrossRefPubMed

15.

Rinaldi C, Salvatore E, Giordano I, De Matteis S, Tucci T, Cinzia VR, Rossi F, Castaldo I, Morra VB, Di Maio L, Filla A, De Michele G (2012) Predictors of survival in a Huntington’s disease population from southern Italy. Can J Neurol Sci J Can Sci Neurol 39:48–51CrossRef

16.

Trembath MK, Horton ZA, Tippett L, Hogg V, Collins VR, Churchyard A, Velakoulis D, Roxburgh R, Delatycki MB (2010) A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov Disord Off J Mov Disord Soc 25:1444–1450. https://doi.org/10.1002/mds.23108 CrossRef

17.

Lipe H, Bird T (2009) Late onset Huntington Disease: clinical and genetic characteristics of 34 cases. J Neurol Sci 276:159–162. https://doi.org/10.1016/j.jns.2008.09.029 CrossRefPubMed

18.

Andresen JM, Gayán J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA, US Venezuela Collaborative Research Group, Cardon LR, Housman DE, Wexler NS (2007) Replication of twelve association studies for Huntington’s disease residual age of onset in large Venezuelan kindreds. J Med Genet 44:44–50. https://doi.org/10.1136/jmg.2006.045153 CrossRefPubMed

19.

Andresen JM, Gayán J, Djoussé L, Roberts S, Brocklebank D, Cherny SS, US-Venezuela Collaborative Research Group, HD MAPS Collaborative Research Group, Cardon LR, Gusella JF, MacDonald ME, Myers RH, Housman DE, Wexler NS (2007) The relationship between CAG repeat length and age of onset differs for Huntington’s disease patients with juvenile onset or adult onset. Ann Hum Genet 71:295–301. https://doi.org/10.1111/j.1469-1809.2006.00335.x CrossRefPubMed

20.

Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E, Predict-HD Investigators of the Huntington Study Group (2006) Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 63:883–890. https://doi.org/10.1001/archneur.63.6.883 CrossRefPubMed

21.

Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, Predict-HD Investigators and Coordinators of the Huntington Study Group (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880. https://doi.org/10.1136/jnnp.2007.128728 CrossRefPubMed

22.

Alonso ME, Yescas P, Rasmussen A, Ochoa A, Macías R, Ruiz I, Suástegui R (2002) Homozygosity in Huntington’s disease: new ethical dilemma caused by molecular diagnosis. Clin Genet 61:437–442CrossRefPubMed

23.

Dürr A, Hahn-Barma V, Brice A, Pêcheux C, Dodé C, Feingold J (1999) Homozygosity in Huntington’s disease. J Med Genet 36:172–173PubMedPubMedCentral

24.

Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi A-C, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD (2003) Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain J Neurol 126:946–955CrossRef

25.

Ha AD, Fung VSC (2012) Huntington’s disease. Curr Opin Neurol 25:491–498. https://doi.org/10.1097/WCO.0b013e3283550c97 CrossRefPubMed

26.

Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP (2008) The relationship between CAG repeat length and clinical progression in Huntington’s disease. Mov Disord Off J Mov Disord Soc 23:1223–1227. https://doi.org/10.1002/mds.21988 CrossRef

27.

Rosenblatt A, Kumar BV, Mo A, Welsh CS, Margolis RL, Ross CA (2012) Age, CAG repeat length, and clinical progression in Huntington’s disease. Mov Disord Off J Mov Disord Soc 27:272–276. https://doi.org/10.1002/mds.24024 CrossRef

28.

Rosenblatt A, Liang K-Y, Zhou H, Abbott MH, Gourley LM, Margolis RL, Brandt J, Ross CA (2006) The association of CAG repeat length with clinical progression in Huntington disease. Neurology 66:1016–1020. https://doi.org/10.1212/01.wnl.0000204230.16619.d9 CrossRefPubMed

29.

Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I (2000) Rate of functional decline in Huntington’s disease. Huntingt Study Group Neurol 54:452–458

30.

Stout JC, Queller S, Baker KN, Cowlishaw S, Sampaio C, Fitzer-Attas C, Borowsky B, HD-CAB Investigators (2014) HD-CAB: a cognitive assessment battery for clinical trials inHuntington’s disease 1,2,3. Mov Disord Off J Mov Disord Soc 29:1281–1288. https://doi.org/10.1002/mds.25964 CrossRef

31.

Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, TRACK-HD Investigators (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649. https://doi.org/10.1016/S1474-4422(13)70088-7 CrossRefPubMed

32.

van Oostrom JCH, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van der Duin L, Pruim J, Roos RC, Leenders KL (2005) Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 65:941–943. https://doi.org/10.1212/01.wnl.0000176071.08694.cc CrossRefPubMed

33.

Aziz NA, van der Burg JMM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group, Roos R (2008) Weight loss in Huntington disease increases with higher CAG repeatnumber. Neurology 71:1506–1513. https://doi.org/10.1212/01.wnl.0000334276.09729.0e CrossRefPubMed

34.

van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA (2017) Body weight is a robust predictor of clinical progression in Huntington disease. Ann Neurol 82:479–483. https://doi.org/10.1002/ana.25007 CrossRefPubMed

35.

Keum JW, Shin A, Gillis T, Mysore JS, Abu Elneel K, Lucente D, Hadzi T, Holmans P, Jones L, Orth M, Kwak S, MacDonald ME, Gusella JF, Lee J-M (2016) The HTT CAG-expansion mutation determines age at death but not disease duration in huntington disease. Am J Hum Genet 98:287–298. https://doi.org/10.1016/j.ajhg.2015.12.018 CrossRefPubMedPubMedCentral

36.

Hadzi TC, Hendricks AE, Latourelle JC, Lunetta KL, Cupples LA, Gillis T, Mysore JS, Gusella JF, MacDonald ME, Myers RH, Vonsattel J-P (2012) Assessment of cortical and striatal involvement in 523 Huntington disease brains. Neurology 79:1708–1715. https://doi.org/10.1212/WNL.0b013e31826e9a5d CrossRefPubMedPubMedCentral

37.

Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577CrossRefPubMed

38.

Culjkovic B, Stojkovic O, Vojvodic N, Svetel M, Rakic L, Romac S, Kostic V (1999) Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington’s disease. J Neurol 246:1090–1093CrossRefPubMed

39.

Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41:689–692. https://doi.org/10.1002/ana.410410521 CrossRefPubMed

40.

Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch SM (2011) A tale of two factors: what determines the rate of progression in Huntington’s disease? A longitudinal MRI study. Mov Disord Off J Mov Disord Soc 26:1691–1697. https://doi.org/10.1002/mds.23762 CrossRef

41.

Koenig KA, Lowe MJ, Harrington DL, Lin J, Durgerian S, Mourany L, Paulsen JS, Rao SM, PREDICT-HD Investigators of the Huntington Study Group (2014) Functional connectivity of primary motor cortex is dependent on genetic burden in prodromal Huntington disease. Brain Connect 4:535–546. https://doi.org/10.1089/brain.2014.0271 CrossRefPubMedPubMedCentral

42.

Wu D, Faria AV, Younes L, Mori S, Brown T, Johnson H, Paulsen JS, Ross CA, Miller MI, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2017) Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington’s disease. Hum Brain Mapp 38:5035–5050. https://doi.org/10.1002/hbm.23713 CrossRefPubMedPubMedCentral

43.

Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, Long JD, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2012) Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 71:822–828. https://doi.org/10.1016/j.biopsych.2011.07.030 CrossRefPubMed

44.

Orth M, Gregory S, Scahill RI, Mayer IS, Minkova L, Klöppel S, Seunarine KK, Boyd L, Borowsky B, Reilmann R, Bernhard Landwehrmeyer G, Leavitt BR, Roos RA, Durr A, Rees G, Rothwell JC, Langbehn D, Tabrizi SJ, TRACK-On Investigators (2016) Natural variation in sensory-motor white matter organization influences manifestations of Huntington’s disease. Hum Brain Mapp 37:4615–4628. https://doi.org/10.1002/hbm.23332 CrossRefPubMedPubMedCentral

45.

Phillips O, Sanchez-Castaneda C, Elifani F, Maglione V, Di Pardo A, Caltagirone C, Squitieri F, Sabatini U, Di Paola M (2013) Tractography of the corpus callosum in Huntington’s disease. PloS One 8:e73280. https://doi.org/10.1371/journal.pone.0073280 CrossRefPubMedPubMedCentral

46.

Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F (2012) 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging 39:1030–1036. https://doi.org/10.1007/s00259-012-2114-z CrossRefPubMed

47.

Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp 32:258–270. https://doi.org/10.1002/hbm.21008 CrossRefPubMed

48.

Reetz K, Romanzetti S, Dogan I, Saß C, Werner CJ, Schiefer J, Schulz JB, Shah NJ (2012) Increased brain tissue sodium concentration in Huntington’s disease—a sodium imaging study at 4 T. NeuroImage 63:517–524. https://doi.org/10.1016/j.neuroimage.2012.07.009 CrossRefPubMed

49.

Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP, Marek KL (2014) The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol 71:1520–1528. https://doi.org/10.1001/jamaneurol.2014.1954 CrossRefPubMed

50.

Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G, Vandenberghe W (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med Off Publ Soc Nucl Med 51:1413–1417. https://doi.org/10.2967/jnumed.110.077156 CrossRef

51.

Pagano G, Niccolini F, Politis M (2016) Current status of PET imaging in Huntington’s disease. Eur J Nucl Med Mol Imaging 43:1171–1182. https://doi.org/10.1007/s00259-016-3324-6 CrossRefPubMedPubMedCentral

52.

Matusch A, Saft C, Elmenhorst D, Kraus PH, Gold R, Hartung H-P, Bauer A (2014) Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington’s disease. Eur J Nucl Med Mol Imaging 41:1210–1220. https://doi.org/10.1007/s00259-014-2724-8 CrossRefPubMed

53.

Weeks RA, Ceballos-Baumann A, Piccini P, Boecker H, Harding AE, Brooks DJ (1997) Cortical control of movement in Huntington’s disease. A PET activation study. Brain J Neurol 120(Pt 9):1569–1578CrossRef

54.

Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66:1638–1643. https://doi.org/10.1212/01.wnl.0000222734.56412.17 CrossRefPubMed

55.

Aylward EH, Harrington DL, Mills JA, Nopoulos PC, Ross CA, Long JD, Liu D, Westervelt HK, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2013) Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntingt Dis 2:477–489. https://doi.org/10.3233/JHD-130076 CrossRef

56.

Barrios FA, Gonzalez L, Favila R, Alonso ME, Salgado PM, Diaz R, Fernandez-Ruiz J (2007) Olfaction and neurodegeneration in HD. Neuroreport 18:73–76. https://doi.org/10.1097/WNR.0b013e3280102302 CrossRefPubMed

57.

Braak H, Braak E (1992) Allocortical involvement in Huntington’s disease. Neuropathol Appl Neurobiol 18:539–547CrossRefPubMed

58.

Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC (2017) Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a024240 CrossRefPubMedPubMedCentral

59.

Jones L, Hughes A (2011) Pathogenic mechanisms in Huntington’s disease. Int Rev Neurobiol 98:373–418. https://doi.org/10.1016/B978-0-12-381328-2.00015-8 CrossRefPubMed

60.

Kalathur RKR, Pedro Pinto J, Sahoo B, Chaurasia G, Futschik ME (2017) HDNetDB: a molecular interaction database for network-oriented investigations into Huntington’s disease. Sci Rep 7:5216. https://doi.org/10.1038/s41598-017-05224-0 CrossRefPubMedPubMedCentral

61.

Saudou F, Humbert S (2016) The biology of Huntingtin. Neuron 89(5):910–926. https://doi.org/10.1016/j.neuron.2016.02.003 CrossRefPubMed

62.

Labbadia J, Morimoto RI (2013) Huntington’s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38(8):378–385. https://doi.org/10.1016/j.tibs.2013.05.003 CrossRefPubMedPubMedCentral

63.

Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha GH, Ukani L, Chepanoske CL, Zhen Y, Sahasrabudhe S, Olson J, Kurschner C, Ellerby LM, Peltier JM, Botas J, Hughes RE (2007) Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 3(5):e82CrossRefPubMedPubMedCentral

64.

Culver BP, Savas JN, Park SK, Choi JH, Zheng S, Zeitlin SO, Yates JR 3rd, Tanese N (2012) Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. J Biol Chem 28:21599–21614. https://doi.org/10.1074/jbc.M112.359307 CrossRef

65.

Ratovitski T, Chighladze E, Arbez N, Boronina T, Herbrich S, Cole RN, Ross CA (2012) Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell Cycle 11:2006–2021. https://doi.org/10.4161/cc.20423 CrossRefPubMedPubMedCentral

66.

Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boontheung P, Geschwind DH, Botas J, Coppola G, Horvath S, Loo JA, Yang XW (2012) Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 75:41–57. https://doi.org/10.1016/j.neuron.2012.05.024 CrossRefPubMedPubMedCentral

67.

Novak MJU, Seunarine KK, Gibbard CR, Hobbs NZ, Scahill RI, Clark CA, Tabrizi SJ (2014) White matter integrity in premanifest and early Huntington’s disease is related to caudate loss and disease progression. Cortex J Devoted Study Nerv Syst Behav 52:98–112. https://doi.org/10.1016/j.cortex.2013.11.009 CrossRef

68.

Macdonald V, Halliday G (2002) Pyramidal cell loss in motor cortices in Huntington’s disease. Neurobiol Dis 10:378–386CrossRefPubMed

69.

Thu DCV, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, Luthi-Carter R, Waldvogel HJ, Faull RLM (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington’s disease. Brain J Neurol 133:1094–1110. https://doi.org/10.1093/brain/awq047 CrossRef

70.

Harrington DL, Rubinov M, Durgerian S, Mourany L, Reece C, Koenig K, Bullmore E, Long JD, Paulsen JS, PREDICT-HD investigators of the Huntington Study Group, Rao SM (2015) Network topology and functional connectivity disturbances precede the onset of Huntington’s disease. Brain J Neurol 138:2332–2346. https://doi.org/10.1093/brain/awv145 CrossRef

71.

Seiss E, Praamstra P, Hesse CW, Rickards H (2003) Proprioceptive sensory function in Parkinson’s disease and Huntington’s disease: evidence from proprioception-related EEG potentials. Exp Brain Res 148:308–319. https://doi.org/10.1007/s00221-002-1291-6 CrossRefPubMed

72.

Cheng C-H, Soong B-W, Hsu W-Y, Lin Y-Y (2014) Reduced automatic frontal response to auditory deviance in Huntington’s disease as indexed by magnetic mismatch negativity. J Clin Neurosci Off J Neurosurg Soc Australas 21:1773–1778. https://doi.org/10.1016/j.jocn.2014.01.019 CrossRef

73.

Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F (2008) Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 79:130–135. https://doi.org/10.1136/jnnp.2007.116244 CrossRefPubMed

74.

Labuschagne I, Cassidy AM, Scahill RI, Johnson EB, Rees E, O’Regan A, Queller S, Frost C, Leavitt BR, Dürr A, Roos R, Owen G, Borowsky B, Tabrizi SJ, Stout JC, TRACK-HD Investigators (2016) Visuospatial processing deficits linked to posterior brain regions in premanifest and early stage Huntington’s disease. J Int Neuropsychol Soc JINS 22:595–608. https://doi.org/10.1017/S1355617716000321 CrossRefPubMed

75.

van den Bogaard SJA, Dumas EM, Ferrarini L, Milles J, van Buchem MA, van der Grond J, Roos R (2011) Shape analysis of subcortical nuclei in Huntington’s disease, global versus local atrophy—results from the TRACK-HD study. J Neurol Sci 307:60–68. https://doi.org/10.1016/j.jns.2011.05.015 CrossRefPubMed

76.

Majid DSA, Aron AR, Thompson W, Sheldon S, Hamza S, Stoffers D, Holland D, Goldstein J, Corey-Bloom J, Dale AM (2011) Basal ganglia atrophy in prodromal Huntington’s disease is detectable over one year using automated segmentation. Mov Disord Off J Mov Disord Soc 26:2544–2551. https://doi.org/10.1002/mds.23912 CrossRef

77.

Waldvogel HJ, Kim EH, Tippett LJ, Vonsattel J-PG, Faull RLM (2015) The neuropathology of Huntington’s disease. Curr Top Behav Neurosci 22:33–80. https://doi.org/10.1007/7854_2014_354 CrossRefPubMed

78.

de Azevedo PC, Guimarães RP, Piccinin CC, Piovesana LG, Campos LS, Zuiani JR, Tamashiro EM, Pinheiro G, Amato-Filho AC, Cendes F, Lopes-Cendes I, D’Abreu A (2017) cerebellar gray matter alterations in huntington disease: a voxel-based morphometry study. Cerebellum Lond Engl 16:923–928. https://doi.org/10.1007/s12311-017-0865-6 CrossRef

79.

Rüb U, Hentschel M, Stratmann K, Brunt E, Heinsen H, Seidel K, Bouzrou M, Auburger G, Paulson H, Vonsattel J-P, Lange H, Korf H-W, den Dunnen W (2014) Huntington’s disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem. Brain Pathol Zurich Switz 24:247–260. https://doi.org/10.1111/bpa.12115 CrossRef

80.

Fielding J, Georgiou-Karistianis N, Bradshaw J, Millist L, Churchyard A, Chiu E, White O (2004) Impaired modulation of the vestibulo-ocular reflex in Huntington’s disease. Mov Disord Off J Mov Disord Soc 19:68–75. https://doi.org/10.1002/mds.10658 CrossRef

Title: Multiple clinical features of Huntington’s disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration
Authors: Sonia Podvin
Holly T. Reardon
Katrina Yin
Charles Mosier
Vivian Hook
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 3/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-8940-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Multiple clinical features of Huntington’s disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Population studies highlight an increased risk of dementia in both dependent and non-dependent drinkers

Patient MW: transient visual hemi-agnosia

Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study

Expanding the importance of HMERF titinopathy: new mutations and clinical aspects

Kennedy’s disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease

Mills’ syndrome revisited